1849. Tigecycline Susceptibility Trends Among Pathogens Isolated from Complicated Skin and Soft Tissue Infections in North and Latin America: 2011-2015
Session: Poster Abstract Session: Antibacterial Susceptibility Surveillance
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • P11_CSSI_Pfizer_IDweek_2016_V1 final.pdf (296.2 kB)
  •   Background: The Tigecycline Evaluation Surveillance Trial (TEST) monitors the activity of tigecycline and other antimicrobials against clinically-relevant pathogens collected globally. This study reports the activity of tigecycline (TGC) for gram-positive and –negative isolates collected in North and Latin America from patients with complicated skin and soft tissue infections (CSSTI). Methods:  There were 378 cumulative sites from North America (NA) and 133 cumulative sites from Latin America (LA) between 2011 and 2015. Non-duplicate clinical gram-positive and -negative isolates from medical centers in NA and LA were collected from various skin and skin structure sources during 2011-2015. Organism identification and antibiotic susceptibility (S) testing was performed by the local laboratories.  Susceptibility testing was performed using broth microdilution according to CLSI guidelines and categorical interpretation of results was done using CLSI or FDA breakpoint criteria where appropriate. Cefoxitin disk testing was performed for all S. aureus to determine methicillin susceptibility MRSA and MSSA. Results: The table provides MIC90 and %S data for TGC against CSSTI isolates

     

    Region %S /MIC90

    North America

    Latin America

    Organism

    n

    %S

    MIC90

    n

    %S

    MIC90

    S. aureus

    2518

    100

    0.12

    509

    100

    0.25

    S. agalactiae

    527

    100

    0.12

    83

    100

    0.06

    Enterococcus spp.

    746

    99.5

    0.12

    193

    100

    0.25

    A. baumannii

    412

    na*

    1

    115

    na

    2

    Enterobacter spp.

    1030

    96.6

    1

    222

    94.1

    2

    E. coli

    790

    99.9

    0.25

    332

    100

    0.5

    K. pneumoniae

    527

    95.1

    1

    191

    92.7

    2

    *na = not applicable for this species

    Conclusion: Based on %S and MIC90 data TGC exhibited potent activity against isolates from all organism groups from complicated skin and soft tissue infections, regardless of the geographic source.  However, given the potential many of these organisms have for developing resistance, continued and careful surveillance monitoring is warranted.

     

    Douglas Biedenbach, MS1, Martha Renteria, MD1, Heidi Leister-Tebbe, BSN2 and Dan Sahm, PhD1, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)Pfizer, Inc., Collegeville, PA

    Disclosures:

    D. Biedenbach, IHMA, Inc.: Independent Contractor , Research support

    M. Renteria, IHMA, Inc.: Independent Contractor , Research support

    H. Leister-Tebbe, Pfizer, Inc.: Employee , Salary

    D. Sahm, IHMA, Inc.: Independent Contractor , Research support

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.